Live Breaking News & Updates on Lexeo Therapeutic

Stay updated with breaking news from Lexeo therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lexeo Therapeutics, Inc. Forecasted to Post FY2027 Earnings of ($2.58) Per Share (NASDAQ:LXEO)

Lexeo Therapeutics, Inc. Forecasted to Post FY2027 Earnings of ($2.58) Per Share (NASDAQ:LXEO)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Leerink Partnrs , Lexeo Therapeutics Inc , Eventide Asset Management , Omega Fund Management , Blackstone Inc , Lexeo Therapeutics , Free Report , Lexeo Therapeutic , Get Free Report , Fund Management , Lexeo Therapeutics Daily ,

Analyzing Entera Bio (NASDAQ:ENTX) and Lexeo Therapeutics (NASDAQ:LXEO)

Entera Bio (NASDAQ:ENTX – Get Free Report) and Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership. Earnings & Valuation This table compares Entera […] ....

Israel General , New York , United States , Amgen Inc , Entera Bio Ltd , Lexeo Therapeutics Inc , Centera Bio , Get Free Report , Lexeo Therapeutics , Lexeo Therapeutic , Given Entera Bio , Fbio Ltd , Entera Bio Daily , Nasdaq Entx , Stock Comparison , Stock Analysis ,

Lexeo Therapeutics, Inc.'s (NASDAQ:LXEO) Quiet Period To Expire on December 13th

Lexeo Therapeutics’ (NASDAQ:LXEO – Get Free Report) quiet period will expire on Wednesday, December 13th. Lexeo Therapeutics had issued 9,090,910 shares in its public offering on November 3rd. The total size of the offering was $100,000,010 based on an initial share price of $11.00. During Lexeo Therapeutics’ quiet period, insiders and underwriters involved in the […] ....

Leerink Partnrs , Stifel Nicolaus , Fund Vilp Omega , Lexeo Therapeutics Inc , Jpmorgan Chase Co , Lexeo Therapeutic , Get Free Report , Lexeo Therapeutics , Lexeo Therapeutics Daily , Nasdaq Lxeo , Lock Up Expiration , Lock Up Period , Quiet Period ,

Lexeo Therapeutics (NASDAQ:LXEO) Receives New Coverage from Analysts at Chardan Capital

Chardan Capital initiated coverage on shares of Lexeo Therapeutics (NASDAQ:LXEO – Free Report) in a report issued on Tuesday, MarketBeat reports. The firm issued a buy rating and a $23.00 price objective on the stock. Chardan Capital also issued estimates for Lexeo Therapeutics’ FY2023 earnings at ($3.30) EPS and FY2024 earnings at ($2.74) EPS. Lexeo […] ....

Fund Vilp Omega , Lexeo Therapeutics Inc , Chardan Capital , Lexeo Therapeutics , Free Report , Lexeo Therapeutic , Get Free Report , Lexeo Therapeutics Daily , Nasdaq Lxeo , Initiated Coverage ,

This biotech stock targeting genetic diseases could nearly double, predicts JPMorgan

This under-the-radar biotech is targeting genetic heart disorders with gene therapies could boost its stock price by 82%, according to JPMorgan. ....

Tessa Romero , Lexeo Therapeutics , Analyst Tessa Romero , Lexeo Therapeutic , Investment Strategy , Stock Markets , Lexeo Therapeutics Inc , Business News ,